SecBot SecBot

AGIO

AGIOS PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001439222 Biotech & Drug Discovery
$37.00 −0.19 (−0.51%)
Oct 23 4:00 PM ET · prev $37.19
Market cap
$2.2B
Mid cap
Consensus
Buy
75% Buy or better · 16 analysts
Median target
🔒 Subscribers only
1 year
−14.6%
from $43.33 · Oct 24
30 days
+12.5%
from $32.90
52-week range
$22.34–45.49
−19% from high · low Nov 19
Avg volume 20D
1.21M
shares / day
Short interest
7.02M
≈11.8% of shares · −7.2%
Days to cover
6.4
at average volume
Insider net
-$1.1M
0 buyers · 1 seller · since Apr 2
New fund stakes
1
Q2 2026 13F · 1 exit
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next FDA decision date, Nov 1, 2026
Strongest NEUTRAL Sarah Gheuens, an officer of Agios Pharmaceuticals, filed a Form 144 on October 22, 2026, indicating intent…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.1M.

  • InstitutionsBULLISH

    Q2 2026: 27 added (1 new), 13 trimmed or exited. Largest new: Point72 Asset Management, $18.8M.

  • AnalystsBULLISH

    12 of 16 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −7.2% to 7.02M shares. 6.4 days to cover, ≈11.8% of shares.

  • TrendUPTREND

    11% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
1
exit
$18.8M
in new stakes
FundMoveSharesValue
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.ADD2,110,809$78.3M
GOLDMAN SACHS GROUP INCADD1,150,932$42.7M
UBS Group AGDOUBLED985,831$36.6M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED810,530$30.1M
Qube Research & Technologies LtdDOUBLED597,638$22.2M
Schonfeld Strategic Advisors LLCDOUBLED520,083$19.3M
Point72 Asset Management, L.P.NEW506,344$18.8M
JANE STREET GROUP, LLCTRIM492,598$18.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 75% rate it Buy or better
Strong Buy5Buy7Hold4Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 7, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 21, 2026B of A Securities
MAINTAIN
MAINTAINBuy
Aug 7, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Jul 31, 2026Citigroup
MAINTAIN
MAINTAINBuy
Jul 31, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Jul 30, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.1M
sold · 1 insider
DateInsiderTypeValue
Oct 22, 2026
Gheuens Sarah
Chief Medical Officer
EXERCISE$12.5K
Oct 22, 2026
Gheuens Sarah
Chief Medical Officer
SELL$18.8K
Oct 21, 2026
Gheuens Sarah
Chief Medical Officer
EXERCISE$37.2K
Oct 21, 2026
Gheuens Sarah
Chief Medical Officer
SELL$55.9K
Aug 4, 2026
Gheuens Sarah
Chief Medical Officer
SELL$914.4K
Jul 8, 2026
Backstrom Jay T.
Director
EXERCISE1,447 sh
Jul 8, 2026
Backstrom Jay T.
Director
AWARD1,447 sh
Jul 1, 2026
Gheuens Sarah
Chief Medical Officer
EXERCISE8,375 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Congressional trades
AGIO trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 0 sells
DateMemberTypeAmountDisclosed
Aug 20, 2026
Gilbert Cisneros
D· HOUSE· Agios Pharmaceuticals Inc
BUY$1,001 - $15,000Sep 11, 2026(23d)
Mar 3, 2026
Gilbert Cisneros
D· HOUSE· Agios Pharmaceuticals Inc
BUY$1,001 - $15,000Apr 8, 2026(37d)

Short side

FINRA· Sep 30, 2026
7,016,166
shares short
-7.2%
vs prior settlement
6.4
days to cover
≈11.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Sarah Gheuens, an officer of Agios Pharmaceuticals, filed a Form 144 on October 22, 2026, indicating intent to sell…
144 — Impact 2/10
Oct 22, 2026 Insider
Gheuens Sarah acquired via exercise 500 shares
Chief Medical Officer @ $25.01 ($12.5K)
Oct 22, 2026 Insider
Gheuens Sarah sold 500 shares
Chief Medical Officer @ $37.52 ($18.8K)
Oct 21, 2026 Insider
Gheuens Sarah acquired via exercise 1,489 shares
Chief Medical Officer @ $25.01 ($37.2K)
Aug 27, 2026 Event
AQVESME
WARNING: HEPATOCELLULAR INJURY AQVESME can cause serious hepatocellular injury. Measure liver labora
Aug 20, 2026 Congress
Gilbert Cisneros buy
$1,001 - $15,000 — House
Aug 7, 2026 Other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Aug 6, 2026 SEC
In Q2 2026, four institutional buyers accumulated $4.9M in AGIO while two sellers trimmed $1.2M, resulting in a net…
INST-CLUSTER — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 1, 2026
FDA decision date
🔒 Fresh data — subscribers only
Nov 5, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 27, 2026
FDA
AQVESME
WARNING: HEPATOCELLULAR INJURY AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and to
Aug 7, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the…
Jul 30, 2026
Earnings
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Agios announces second quarter 2026 financial results and provides business update.
Jul 30, 2026
Earnings date
AGIO Q2 2026 Earnings Scheduled — 2026-07-30
Jul 21, 2026
Press release
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Agios provides update on Phase 2 trial of tebapivat in sickle cell disease

SecBot reports

11 filings · 4 press releases · 3 bullish · 0 bearish · 1 mixed · 7 neutral
All AGIO filing & press-release reports (15)